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Germline mutations in the human DNA mismatch
repair (MMR) genes MSH2 and MLH1 are associated
with the inherited cancer disorder Lynch syndrome (LS).
Up to 30% of MLH1 variants found are missense muta-
tions. The functional consequences in regard to patho-
genicity of many of these variants are unclear. Missense
mutations affect protein structure or function, but may
also cause aberrant splicing. In this study, in silico
prediction tools (SIFT, PolyPhen-2 and ESEfinder 3.0),
literature and an online MMR mutation database review
were used to evaluate the clinical significance of 26
MLH1 missense mutations identified in patients from
Polish families, suspected of Lynch syndrome. Six MLH1
VUS were classified as pathogenic, nine MLH1 missense
mutations are classified as neutral. 11 variants require
additional research. The results show that in silico pre-
diction tools can be utilized in an appropriate and effi-
cient manner to determine the pathogenicity of MMR
gene variations.
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